Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of radiolabeled ABBV-932 in healthy male volunteers
NL-OMON58882Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABBV-932, sponsored by AbbVie Inc. Primary endpoint: Primary endpoint(s). Started Apr 2026; status: completed.
02
Drugs
ABBV-932
Beyond the preview
Go deeper on NL-OMON58882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58882.